There's no evidence to support your claim that Gerald was the most qualified and ONLY guy to fill the CEO spot when Cleary stepped down. Gerald had been with the company for 5 years in various roles, and had an outstanding educational background which certainly qualified him for the role, regardless of prior CEO experience. Every CEO in business has to start in the role with zero CEO experience. Gerald is no different.

I have no idea why Cleary resigned. Maybe the board decided a fresh approach was needed. Amarantus isn't your typical start-up biotech. They are taking a broad de-risking approach for multiple assets, and perhaps Cleary's prior experience was not suited for this kind of development. Only the insiders know what really happened.

I don't speculate on what BP's interest regarding Gerald may or may not be. Our management has stated multiple times in conference calls that there is significant interest from pharma companies in our products. We're never going to be told of possible pharma offers unless the company chooses to accept, so the lack of news on this topic doesn't prove lack of pharma interest... it only fuels speculation from nervous investors.